FOLD [NASD]
Amicus Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own0.90% Shs Outstand288.48M Perf Week-1.94%
Market Cap2.03B Forward P/E- EPS next Y-0.15 Insider Trans-5.99% Shs Float249.85M Perf Month-3.07%
Income-270.10M PEG- EPS next Q-0.21 Inst Own- Short Float10.87% Perf Quarter-8.00%
Sales317.80M P/S6.40 EPS this Y13.70% Inst Trans1.20% Short Ratio7.13 Perf Half Y-32.47%
Book/sh0.83 P/B9.14 EPS next Y83.00% ROA-31.10% Target Price14.33 Perf Year-12.86%
Cash/sh1.53 P/C4.94 EPS next 5Y- ROE-95.00% 52W Range5.91 - 12.63 Perf YTD-34.29%
Dividend- P/FCF- EPS past 5Y9.10% ROI-30.90% 52W High-39.90% Beta1.36
Dividend %- Quick Ratio3.80 Sales past 5Y128.00% Gross Margin88.80% 52W Low28.43% ATR0.46
Employees496 Current Ratio4.00 Sales Q/Q18.50% Oper. Margin-72.10% RSI (14)50.37 Volatility4.96% 7.16%
OptionableYes Debt/Eq1.63 EPS Q/Q-19.00% Profit Margin-85.00% Rel Volume0.53 Prev Close7.94
ShortableYes LT Debt/Eq1.63 EarningsMay 09 BMO Payout- Avg Volume3.81M Price7.59
Recom2.00 SMA206.30% SMA50-8.00% SMA200-23.58% Volume2,023,098 Change-4.41%
Apr-13-22Resumed Goldman Neutral $11
Jan-14-22Upgrade SVB Leerink Mkt Perform → Outperform $12 → $16
Nov-15-21Upgrade Stifel Hold → Buy $12 → $16
Sep-30-21Upgrade JP Morgan Neutral → Overweight $16
Jul-19-21Resumed BTIG Research Buy $15
May-27-21Initiated Needham Hold
May-21-21Initiated UBS Buy $16
Apr-14-21Upgrade Cantor Fitzgerald Neutral → Overweight $17
Mar-02-21Initiated Stifel Hold $13
Feb-12-21Downgrade JP Morgan Overweight → Neutral $19
Feb-12-21Downgrade Cantor Fitzgerald Overweight → Neutral $30 → $17
Dec-28-20Resumed Cantor Fitzgerald Overweight $20 → $30
Dec-10-20Downgrade Citigroup Buy → Neutral $20 → $27
Nov-11-20Initiated Berenberg Hold
Jun-17-20Initiated BTIG Research Buy $19
Feb-04-20Resumed Cantor Fitzgerald Overweight $19 → $20
Nov-12-19Reiterated H.C. Wainwright Buy $18 → $20
Jun-17-19Initiated H.C. Wainwright Buy $18
Jun-05-19Reiterated Cantor Fitzgerald Overweight $20 → $19
Apr-05-19Initiated Janney Buy
May-10-22 04:01PM  
02:36PM  
May-09-22 09:15AM  
08:25AM  
07:00AM  
May-06-22 03:48PM  
03:38PM  
03:02PM  
09:44AM  
08:40AM  
May-05-22 09:55AM  
May-04-22 07:00AM  
May-03-22 08:55AM  
May-02-22 03:00PM  
Apr-26-22 07:00AM  
Apr-19-22 07:00AM  
Mar-28-22 07:06PM  
Mar-16-22 10:02AM  
07:00AM  
Mar-10-22 07:00AM  
Mar-04-22 08:03PM  
Mar-01-22 07:00AM  
Feb-24-22 10:35AM  
07:00AM  
07:00AM  
Feb-17-22 03:03PM  
03:07AM  
Feb-10-22 09:15AM  
07:00AM  
Feb-09-22 05:39AM  
Feb-07-22 01:18PM  
07:00AM  
Jan-13-22 02:26AM  
Jan-10-22 07:00AM  
Jan-05-22 07:00AM  
Dec-28-21 09:38AM  
Dec-26-21 07:46AM  
Dec-21-21 09:38AM  
Dec-16-21 09:38AM  
Dec-10-21 12:10PM  
Dec-08-21 09:38AM  
Dec-06-21 11:51AM  
Dec-03-21 07:00AM  
Nov-24-21 07:00AM  
Nov-22-21 07:00AM  
Nov-18-21 07:00AM  
Nov-11-21 07:00AM  
06:42AM  
Nov-10-21 10:42AM  
Nov-09-21 04:00PM  
08:25AM  
07:00AM  
Nov-04-21 11:16AM  
Nov-03-21 09:20AM  
07:00AM  
Oct-28-21 03:06PM  
Oct-27-21 10:02AM  
Oct-26-21 12:05PM  
Oct-23-21 06:08AM  
01:04AM  
Oct-19-21 02:00PM  
10:57AM  
Oct-15-21 08:49AM  
Oct-12-21 05:36AM  
Oct-11-21 10:24AM  
Oct-05-21 12:17PM  
Oct-04-21 05:44PM  
Sep-30-21 12:26PM  
08:18AM  
06:24AM  
Sep-29-21 05:30PM  
03:02PM  
08:13AM  
06:30AM  
06:30AM  
Sep-20-21 07:00AM  
Sep-16-21 08:12AM  
Sep-03-21 07:00AM  
Aug-09-21 12:43PM  
Aug-06-21 12:24PM  
Aug-05-21 07:00PM  
08:35AM  
07:00AM  
Aug-04-21 07:00AM  
Aug-02-21 07:00AM  
Jul-29-21 03:05PM  
Jul-27-21 07:00AM  
Jul-06-21 10:06AM  
Jun-22-21 07:21AM  
06:00AM  
Jun-14-21 07:00AM  
Jun-09-21 11:30AM  
Jun-08-21 07:00AM  
Jun-03-21 06:48AM  
May-29-21 04:00AM  
May-28-21 07:00AM  
May-21-21 07:00AM  
May-11-21 11:55AM  
May-10-21 06:30PM  
09:05AM  
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCGLYNN MARGARET GDirectorMay 02Option Exercise4.7915,00071,85053,034May 04 07:37 PM
RAAB MICHAELDirectorMay 02Option Exercise4.7915,00071,85051,749May 04 07:30 PM
RAAB MICHAELDirectorMay 02Sale6.9915,000104,89036,749May 04 07:30 PM
MCGLYNN MARGARET GDirectorMay 02Sale6.9915,000104,89638,034May 04 07:37 PM
Crowley John FChairman & CEOApr 19Sale8.018,25466,082965,967Apr 20 05:39 PM
Crowley John FChairman & CEOApr 18Sale8.042,21417,794974,221Apr 20 05:39 PM
Rosenberg EllenChief Legal OfficerApr 07Sale9.0611,01899,797302,952Apr 08 07:33 PM
Campbell Bradley LChief Operating OfficerMar 18Option Exercise3.5310,94038,618595,955Mar 22 06:44 PM
Campbell Bradley LChief Operating OfficerMar 18Sale10.0010,940109,426585,015Mar 22 06:44 PM
SBLENDORIO GLENNDirectorMar 04Option Exercise4.7915,00071,85059,048Mar 07 05:54 PM
Crowley John FChairman & CEOJan 18Sale10.238,56487,610976,435Jan 19 06:43 PM
Crowley John FChairman & CEOJan 05Sale12.1863,543774,119655,131Jan 07 05:20 PM
Campbell Bradley LChief Operating OfficerJan 03Option Exercise3.535,47019,309412,211Jan 04 08:58 PM
Campbell Bradley LChief Operating OfficerJan 03Sale11.865,47064,880406,741Jan 04 08:58 PM
Campbell Bradley LChief Operating OfficerDec 22Option Exercise4.383,00013,140460,268Dec 23 04:14 PM
Campbell Bradley LChief Operating OfficerDec 22Sale11.703,00035,096457,268Dec 23 04:14 PM
Campbell Bradley LChief Operating OfficerDec 01Option Exercise4.3810,51546,056467,783Dec 02 08:42 PM
Campbell Bradley LChief Operating OfficerDec 01Sale11.0010,515115,706457,268Dec 02 08:42 PM
Crowley John FChairman & CEONov 15Option Exercise4.3824,935109,215849,461Nov 17 07:30 PM
Crowley John FChairman & CEONov 15Sale11.7524,935292,951824,526Nov 17 07:30 PM
Crowley John FChairman & CEONov 03Option Exercise3.8227,739105,963852,265Nov 03 06:30 PM
Crowley John FChairman & CEONov 03Sale12.0027,739332,868824,526Nov 03 06:30 PM
Campbell Bradley LChief Operating OfficerNov 01Option Exercise4.3810,51546,056467,783Nov 03 06:29 PM
WHITMAN BURKE WDirectorNov 01Buy10.491,50015,73565,082Nov 03 06:31 PM
Crowley John FChairman & CEONov 01Sale10.807,81984,451824,526Nov 03 06:30 PM
Campbell Bradley LChief Operating OfficerNov 01Sale11.3210,515119,054457,268Nov 03 06:29 PM
Crowley John FChairman & CEOOct 15Option Exercise4.3822,00096,360854,345Oct 18 09:42 PM
Crowley John FChairman & CEOOct 15Sale11.2222,000246,871832,345Oct 18 09:42 PM
Campbell Bradley LChief Operating OfficerOct 01Option Exercise4.3810,51546,056467,783Oct 04 06:58 PM
WHITMAN BURKE WDirectorOct 01Buy9.561,50014,34663,582Oct 04 07:00 PM
Crowley John FChairman & CEOOct 01Sale10.007,50075,000832,345Oct 04 06:59 PM
Campbell Bradley LChief Operating OfficerOct 01Sale10.0010,515105,150457,268Oct 04 06:58 PM
Crowley John FChairman & CEOSep 15Option Exercise4.3822,00096,360861,845Sep 17 05:27 PM
Crowley John FChairman & CEOSep 15Sale11.0822,000243,828839,845Sep 17 05:27 PM
Prout SamanthaPrincipal Accounting OfficerSep 03Option Exercise9.754,92548,00488,095Sep 08 06:42 PM
Crowley John FChairman & CEOSep 03Option Exercise3.735,23819,563845,083Sep 08 06:45 PM
Prout SamanthaPrincipal Accounting OfficerSep 03Sale12.014,92559,16883,170Sep 08 06:42 PM
Crowley John FChairman & CEOSep 03Sale12.025,23862,944839,845Sep 08 06:45 PM
Campbell Bradley LChief Operating OfficerSep 01Option Exercise4.3810,51546,056467,783Sep 07 06:56 PM
WHITMAN BURKE WDirectorSep 01Buy11.411,50017,11562,082Sep 07 06:53 PM
Crowley John FChairman & CEOSep 01Sale11.507,50086,250839,845Sep 07 06:55 PM
Campbell Bradley LChief Operating OfficerSep 01Sale11.5010,515120,905457,268Sep 07 06:56 PM
Prout SamanthaPrincipal Accounting OfficerAug 23Sale11.005,04555,49583,170Aug 25 05:55 PM
Crowley John FChairman & CEOAug 16Option Exercise4.3822,00096,360869,345Aug 18 06:36 PM
Crowley John FChairman & CEOAug 16Sale10.2722,000225,918847,345Aug 18 06:36 PM
Campbell Bradley LChief Operating OfficerAug 05Option Exercise4.3821,02892,103478,296Aug 09 08:19 PM
Crowley John FChairman & CEOAug 05Option Exercise4.3822,00096,360884,345Aug 09 08:21 PM
Campbell Bradley LChief Operating OfficerAug 05Sale10.0221,028210,671457,268Aug 09 08:19 PM
Crowley John FChairman & CEOAug 05Sale10.0337,000371,047847,345Aug 09 08:21 PM
WHITMAN BURKE WDirectorAug 02Buy9.281,50013,92060,582Aug 04 05:12 PM
Crowley John FChairman & CEOJul 12Sale9.3114,885138,652862,345Jul 14 09:08 PM
WHITMAN BURKE WDirectorJul 01Buy9.601,50014,40059,082Jul 14 09:09 PM
Crowley John FChairman & CEOJun 15Option Exercise4.3822,00096,360899,230Jun 17 08:06 PM
Crowley John FChairman & CEOJun 15Sale10.2622,000225,632877,230Jun 17 08:06 PM
Campbell Bradley LChief Operating OfficerJun 07Option Exercise3.2173,110234,659474,618Jun 09 07:30 PM
Crowley John FChairman & CEOJun 07Option Exercise6.3122,000138,913906,730Jun 09 07:31 PM
Crowley John FChairman & CEOJun 07Sale10.0129,500295,192877,230Jun 09 07:31 PM
Campbell Bradley LChief Operating OfficerJun 07Sale10.0110,514105,207457,268Jun 09 07:30 PM
WHITMAN BURKE WDirectorJun 01Buy9.241,50013,86147,467Jun 02 06:26 PM
Bleil Lynn DorseyDirectorMay 25Buy8.7428,605250,00850,310May 27 04:16 PM